Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Sees Large Decline in Short Interest

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Get Free Report) was the recipient of a significant decline in short interest during the month of January. As of January 31st, there was short interest totalling 2,940,000 shares, a decline of 6.7% from the January 15th total of 3,150,000 shares. Based on an average daily volume of 708,000 shares, the days-to-cover ratio is currently 4.2 days.

Insider Buying and Selling

In other news, EVP Tolga Tanguler sold 1,469 shares of the firm's stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $250.98, for a total transaction of $368,689.62. Following the completion of the transaction, the executive vice president now directly owns 13,191 shares of the company's stock, valued at $3,310,677.18. This trade represents a 10.02 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CEO Yvonne Greenstreet sold 5,219 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Tuesday, November 26th. The stock was sold at an average price of $250.98, for a total value of $1,309,864.62. Following the transaction, the chief executive officer now owns 78,880 shares of the company's stock, valued at $19,797,302.40. This represents a 6.21 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 81,356 shares of company stock valued at $22,498,551. 1.50% of the stock is owned by insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors have recently added to or reduced their stakes in the company. Huntington National Bank increased its position in shares of Alnylam Pharmaceuticals by 91.8% during the third quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company's stock worth $26,000 after acquiring an additional 45 shares during the last quarter. Larson Financial Group LLC grew its stake in Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 73 shares in the last quarter. Hollencrest Capital Management purchased a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $29,000. R Squared Ltd acquired a new position in shares of Alnylam Pharmaceuticals in the 4th quarter valued at approximately $33,000. Finally, OFI Invest Asset Management purchased a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at approximately $35,000. Institutional investors and hedge funds own 92.97% of the company's stock.

Alnylam Pharmaceuticals Stock Down 0.2 %

Shares of NASDAQ:ALNY traded down $0.41 during mid-day trading on Friday, hitting $250.59. 653,580 shares of the company traded hands, compared to its average volume of 693,794. The firm's 50 day simple moving average is $254.14 and its 200 day simple moving average is $263.02. The firm has a market cap of $32.44 billion, a P/E ratio of -115.48 and a beta of 0.35. The company has a debt-to-equity ratio of 15.27, a quick ratio of 2.71 and a current ratio of 2.78. Alnylam Pharmaceuticals has a 52-week low of $141.98 and a 52-week high of $304.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.62) by ($0.03). On average, equities analysts anticipate that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on ALNY shares. Raymond James upped their price objective on Alnylam Pharmaceuticals from $275.00 to $298.00 and gave the company an "outperform" rating in a research report on Friday, November 1st. Canaccord Genuity Group upped their target price on shares of Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the company a "buy" rating in a report on Tuesday. HC Wainwright reaffirmed a "buy" rating and set a $400.00 price target on shares of Alnylam Pharmaceuticals in a research note on Monday, January 13th. Chardan Capital reissued a "buy" rating and issued a $300.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, November 1st. Finally, Wolfe Research lowered shares of Alnylam Pharmaceuticals from a "peer perform" rating to an "underperform" rating in a research report on Tuesday, November 12th. One research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus price target of $299.48.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.